Simplified Mathematical Modelling of Uncertainty: Cost-Effectiveness of COVID-19 Vaccines in Spain
Open Access
- 5 March 2021
- journal article
- research article
- Published by MDPI AG in Mathematics
- Vol. 9 (5), 566
- https://doi.org/10.3390/math9050566
Abstract
When exceptional situations, such as the COVID-19 pandemic, arise and reliable data is not available at decision-making times, estimation using mathematical models can provide a reasonable reckoning for health planning. We present a simplified model (static but with two-time references) for estimating the cost-effectiveness of the COVID-19 vaccine. A simplified model provides a quick assessment of the upper bound of cost-effectiveness, as we illustrate with data from Spain, and allows for easy comparisons between countries. It may also provide useful comparisons among different vaccines at the marketplace, from the perspective of the buyer. From the analysis of this information, key epidemiological figures, and costs of the disease for Spain have been estimated, based on mortality. The fatality rate is robust data that can alternatively be obtained from death registers, funeral homes, cemeteries, and crematoria. Our model estimates the incremental cost-effectiveness ratio (ICER) to be 5132 € (4926–5276) as of 17 February 2021, based on the following assumptions/inputs: An estimated cost of 30 euros per dose (plus transport, storing, and administration), two doses per person, efficacy of 70% and coverage of 70% of the population. Even considering the possibility of some bias, this simplified model provides confirmation that vaccination against COVID-19 is highly cost-effective.This publication has 42 references indexed in Scilit:
- Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY ThresholdThe New England Journal of Medicine, 2014
- A Direct Method for Measuring Discounting and QALYs More Easily and ReliablyMedical Decision Making, 2012
- Grupos de pacientes Relacionados por el Diagnóstico (GRD) en los hospitales generales españoles: variabilidad en la estancia media y el coste medio por procesoEnfermería Global, 2011
- Using QALYs in CancerPharmacoEconomics, 2011
- Los modelos de Markov probabilísticos en la evaluación económica de tecnologías sanitarias: una guía prácticaGaceta Sanitaria, 2010
- The potential cost-effectiveness of prophylactic human papillomavirus vaccines in CanadaVaccine, 2007
- Drosophila innate immunity: an evolutionary perspectiveNature Immunology, 2002
- Cost–benefits of vaccination programmesVaccine, 2000
- Markov Models in Medical Decision MakingMedical Decision Making, 1993
- Measurement of health state utilities for economic appraisal: A reviewJournal of Health Economics, 1986